A Phase I, Open-Label Study of GSK3174998 Administered Alone and in Combination With Anticancer Agents Including Pembrolizumab in Subjects With Selected Advanced Solid Tumors

Trial Profile

A Phase I, Open-Label Study of GSK3174998 Administered Alone and in Combination With Anticancer Agents Including Pembrolizumab in Subjects With Selected Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs GSK 3174998 (Primary) ; Pembrolizumab (Primary)
  • Indications Breast cancer; Colorectal cancer; Head and neck cancer; Male breast cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms ENGAGE-1
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 30 Nov 2017 Planned End Date changed from 1 Jan 2020 to 31 Jan 2020.
    • 07 Jun 2016 Trial design presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 20 Apr 2016 Trial design presented at the 107th Annual Meeting of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top